Posters and Presentations
12/01/2023
Determinants of Health-Related Quality of Life of Patients With Focal Epilepsy: A Systematic Literature Review
12/01/2023
Characterization of BHV-7000: A Novel Kv7.2/7.3 Activator for the Treatment of Seizures
12/01/2023
Novel, Selective Kv7.2/7.3 Potassium Channel Activator, BHV-7000, Demonstrates Dose-Dependent Pharmacodynamic Effects on EEG Parameters in Healthy Adults
12/01/2023
Functional Impairments in Patients With KCNQ2-DEE: Associations Among Key Clinical Features
12/01/2023
A First in Human Phase 1 Study Evaluating the Safety and Tolerability of BHV-7000, a Novel, Selective Kv7.2/7.3 Potassium Channel Activator, in Healthy Adults
09/02/2023
Discovery and Characterization of BHV-7000: A Novel Kv7.2/7.3 Activator for the Treatment of Epilepsy
03/13/2023
Discovery and Characterization of BHV-7000: A Novel Kv7.2/7.3 Activator for the Treatment of Epilepsy
12/03/2022
Effects of retigabine and the novel M-current activator BHV-7000 on epilepsy-associated KCNQ2 variants
5/25/2023
Understanding the Spectrum of SCA1, SCA2, SCA3, and SCA6 Through the Eyes of Patients: Burden of Illness Perspectives.
6/1/2023
Two Randomized, Double-Blind, Placebo-Controlled Trials of Adjunctive Troriluzole, a Novel Glutamate-Modulating Agent, in Obsessive-Compulsive Disorder
11/17/2022
Two Randomized, Double-Blind, Placebo-Controlled Trials of Adjunctive Troriluzole, a Novel Glutamate-Modulating Agent, in Obsessive-Compulsive Disorder
06/20/2023
Taldefgrobep Alfa: Preclinical and Clinical Data Supporting the Phase 3 RESILIENT Study in Spinal Muscular Atrophy
03/20/2023
Taldefgrobep Alfa: Preclinical and Clinical Data Supporting the Phase 3 RESILIENT Study in Spinal Muscular Atrophy